The risk for acidosis during metformin treatment is no higher than that during alternative treatment among patients with type 2 diabetes and an estimated glomerular filtration rate below 30 mL/min per 1.73 m2, study data show.
The majority of adolescents and young adults with type 2 diabetes are still being treated with metformin and/or insulin, despite a growing number of medications being available for adults, US study data show.
Women with diabetes who use oral antidiabetic agents during the first trimester of pregnancy do not have a greater risk for adverse maternal or fetal outcomes than those using insulin, researchers report.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.
With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.
medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.
The authors report the case of a 31-year-old Caucasian woman with type 2 diabetes who conceived while on therapy with empagliflozin plus metformin and insulin degludec.